Head and Neck cancer (HNC) - Epidemiology Forecast - 2032

DelveInsight's 'Head and Neck Cancer (HNC)- Epidemiology Forecast-2032' report delivers an in-depth understanding of HNC historical and forecasted epidemiology as well as the epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Head and Neck Cancer (HNC) Understanding

Head and Neck Cancer (HNC) Overview

Head and Neck Cancer (HNC) usually begins in the squamous cells - often referred to as squamous cell carcinomas of the head and neck - that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinomas. HNC begins in several places in the head and throat, excluding brain or eye cancer.

The types of HNC include laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity, and paranasal sinus cancer, salivary gland cancer, oral cancer, oropharyngeal cancer and tonsil cancer. Histologically, progression to invasive HNSCC follows an ordered series beginning with epithelial cell hyperplasia, followed by dysplasia (mild, moderate, and severe), carcinoma in situ, and, ultimately, invasive carcinoma.

Continued in the report…

Head and Neck Cancer (HNC) Diagnosis

There are many tests used for diagnosing HNC. The doctor may consider these factors when choosing a diagnostic test:

• The type of cancer suspected
• Signs and symptoms
• Age and general health
• The results of earlier medical tests

If a person has symptoms and signs of HNC, the doctor will take a complete medical history, noting all symptoms and risk factors. In addition, the following tests may be used to diagnose HNC:

Physical examination/blood and urine tests

During a physical examination, the doctor feels for any lumps on the neck, lips, gums, and cheeks. The doctor will also inspect the nose, mouth, throat, and tongue for abnormalities, often using a light and a mirror for a clearer view. Blood tests and urine tests may be done to help diagnose cancer.

Endoscopy

An endoscopy allows the doctor to see inside the body with a thin, lighted, flexible tube called an endoscope. The person may be sedated as the tube is gently inserted through the nose into the throat and down the esophagus to examine the head and neck. The examination has different names depending on the area of the body examined, such as laryngoscopy to view the larynx, pharyngoscopy to view the pharynx, or nasopharyngoscopy to view the nasopharynx. A combination of these procedures is referred to as a panendoscopy.

Continued in the report…

Head and Neck Cancer (HNC) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of HNC, Molecular Stage-specific Incident Cases of HNC, Site-specific Incident Cases of HNC, HPV-specific Incident Cases of HNC, and Molecular Alteration-specific Incident Cases of HNC scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Head and Neck Cancer Cancer (HNC) Detailed Epidemiology Segmentation

• In 2021, the total incident cases of HNC in the 7MM countries were ~158,000, and these cases are anticipated to increase during the study period.

• Among the European countries, Germany had the highest number of incident cases of HNC in 2021, i.e., ~20,000 cases, followed by France which had ~16,000 incident cases in 2021. On the other hand, Italy had the lowest incident cases of HNC, i.e. ~9900 cases in 2021. Japan had ~20,000 incident cases of HNC in 2021.

• The analysis from 2021 suggests that the stage-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for regional, at ~30,000 cases, followed by localized with ~21,000 cases, distant with ~11,000 cases, and ~3,000 cases of the unknown stage.

• In 2021, the molecular alteration-specific incident cases of HNC in the US were maximum for TP53 at ~47,000 cases followed by CCND1, PIK3CA, NOTCH1, KMT2D, EGFR, NSD1, FGFR1, and HRAS mutations that had ~18,000 cases; ~14,000 cases; ~12,400 cases; ~12,000 cases; ~10,000 cases; ~6,500 cases; ~5,700 cases; and ~3,300 cases respectively.

• In 2021, the HPV status-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for HPV negative at ~40,000 cases followed by HPV positive at ~23,000 cases. By 2032, HPV status-specific incident cases of HNC are expected to increase significantly.

Scope of the Report:

• The report covers the descriptive overview of HNC, explaining its causes, signs, and symptoms, pathophysiology, and diagnosis.

• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The report assesses the disease risk and burden.

• The report provides the segmentation of the disease epidemiology for 7MM by segmented by 'Total Incident Cases of HNC, Molecular Stage-specific Incident Cases of HNC, Site-specific Incident Cases of HNC, HPV-specific Incident Cases of HNC, and Molecular Alteration-specific Incident Cases of HNC'.

Report Highlights:

• 11-Year Forecast of HNC
• 7MM Coverage
• Total Incident Cases of HNC
• Molecular Alteration-specific Incident Cases of HNC
• Stage-specific Incident Cases of HNC

Key Questions Answered

• What are the disease risk, burdens, and unmet needs of HNC?

• What is the historical HNC patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?

• What would be the forecasted patient pool of HNC at the 7MM level?

• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HNC?

• Out of the countries mentioned above, which country would have the highest patient population of HNC during the forecast period (2022-2032)?

• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

The Head and Neck Cancer (HNC) report will allow the user to -

• Develop business strategies by understanding the trends, shaping and driving the 7MM HNC epidemiology.

• The HNC epidemiology report and model were written and developed by Masters and PhD level epidemiologists.

• The HNC epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States

• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2019-2032.